Time-fixed univariate and multivariate analysis of OS in the CLL training series
| . | Univariate analysis . | Multivariate analysis . | Internal bootstrapping validation . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bootstrap parameters (mean) . | Bootstrap selection . | |||||||||||
| HR . | LCI . | UCI . | P . | HR . | LCI . | UCI . | P . | HR . | LCI . | UCI . | ||
| Age, y* | 1.06 | 1.04 | 1.07 | < .0001 | 1.06 | 1.04 | 1.07 | < .0001 | 1.06 | 1.04 | 1.97 | 100% |
| Sex | ||||||||||||
| Female | 1.00 | .0138 | 1.00 | .1962 | 1.00 | |||||||
| Male | 1.47 | 1.08 | 2.00 | 1.23 | 0.89 | 1.71 | 1.27 | 0.91 | 1.77 | 50% | ||
| Rai stage | ||||||||||||
| 0-I | 1.00 | < .0001† | 1.00 | < .0001† | 1.00 | |||||||
| II | 1.82 | 1.19 | 2.77 | 1.46 | 0.95 | 2.25 | 1.48 | 0.95 | 2.30 | 100% | ||
| III-IV | 4.19 | 2.99 | 5.87 | 3.08 | 2.16 | 4.39 | 3.33 | 2.31 | 4.79 | 100% | ||
| IGHV homology < 98% | 1.00 | < .0001 | 1.00 | .0036 | 1.00 | |||||||
| IGHV homology > 98% | 2.18 | 1.61 | 2.94 | 1.63 | 1.17 | 2.28 | 1.68 | 1.20 | 2.37 | 94.9% | ||
| Integrated mutational and cytogenetic model | ||||||||||||
| Very-low risk | 1.00 | < .0001† | 1.00 | .0010† | 1.00 | |||||||
| Low-risk | 1.57 | 1.00 | 2.50 | 1.20 | 0.75 | 1.94 | 1.23 | 0.76 | 2.01 | 97.3% | ||
| Intermediate-risk | 2.70 | 1.66 | 4.40 | 1.98 | 1.19 | 3.32 | 2.06 | 1.22 | 3.51 | 97.3% | ||
| High-risk | 4.29 | 2.71 | 6.79 | 2.34 | 1.41 | 3.89 | 2.46 | 1.47 | 4.14 | 97.3% | ||
| . | Univariate analysis . | Multivariate analysis . | Internal bootstrapping validation . | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bootstrap parameters (mean) . | Bootstrap selection . | |||||||||||
| HR . | LCI . | UCI . | P . | HR . | LCI . | UCI . | P . | HR . | LCI . | UCI . | ||
| Age, y* | 1.06 | 1.04 | 1.07 | < .0001 | 1.06 | 1.04 | 1.07 | < .0001 | 1.06 | 1.04 | 1.97 | 100% |
| Sex | ||||||||||||
| Female | 1.00 | .0138 | 1.00 | .1962 | 1.00 | |||||||
| Male | 1.47 | 1.08 | 2.00 | 1.23 | 0.89 | 1.71 | 1.27 | 0.91 | 1.77 | 50% | ||
| Rai stage | ||||||||||||
| 0-I | 1.00 | < .0001† | 1.00 | < .0001† | 1.00 | |||||||
| II | 1.82 | 1.19 | 2.77 | 1.46 | 0.95 | 2.25 | 1.48 | 0.95 | 2.30 | 100% | ||
| III-IV | 4.19 | 2.99 | 5.87 | 3.08 | 2.16 | 4.39 | 3.33 | 2.31 | 4.79 | 100% | ||
| IGHV homology < 98% | 1.00 | < .0001 | 1.00 | .0036 | 1.00 | |||||||
| IGHV homology > 98% | 2.18 | 1.61 | 2.94 | 1.63 | 1.17 | 2.28 | 1.68 | 1.20 | 2.37 | 94.9% | ||
| Integrated mutational and cytogenetic model | ||||||||||||
| Very-low risk | 1.00 | < .0001† | 1.00 | .0010† | 1.00 | |||||||
| Low-risk | 1.57 | 1.00 | 2.50 | 1.20 | 0.75 | 1.94 | 1.23 | 0.76 | 2.01 | 97.3% | ||
| Intermediate-risk | 2.70 | 1.66 | 4.40 | 1.98 | 1.19 | 3.32 | 2.06 | 1.22 | 3.51 | 97.3% | ||
| High-risk | 4.29 | 2.71 | 6.79 | 2.34 | 1.41 | 3.89 | 2.46 | 1.47 | 4.14 | 97.3% | ||
Shrinkage coefficient = 0.97; discrimination: bias-corrected c-index, 0.762; optimism, 0.005; calibration: bias-corrected calibration slope, 0.965; optimism, 0.035.
HR indicates hazard ratio; LCI, 95% lower CI; UCI, 95% upper CI; and IGHV, immunoglobulin heavy variable gene.
Analyzed as a continuous variable.
P for trend.